Topical Uses of Szeto-Schiller Peptides
Provided are methods for improving the appearance aging or of peri-menopausal, menopausal, or post-menopausal skin comprising: applying to the skin tissue of a mammal in need of such regulation, a safe and effective amount of a composition comprising at least one Szeto-Schiller peptide and a dermatologically acceptable carrier. Compositions for use in the methods are also provided.
1 . A method of improving the appearance of peri-menopausal, menopausal, or post-menopausal skin comprising: applying to the skin tissue of a mammal in need of such regulation, a safe and effective amount of a composition comprising at least one Szeto-Schiller peptide and a dermatologically acceptable carrier.
2 . The method of claim 1 wherein the peptide is Tyr-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 1).
3 . The method of claim 1 wherein the peptide is Dmt-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 2).
4 . The method of claim 1 wherein the peptide is Phe-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO. 3).
5 . The method of claim 1 wherein the peptide is D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4).
6 . The method of claim 1 wherein the peptide is in the range from 10 ppm to 1000 ppm.
7 . The method of claim 6 wherein the peptide is the range from 50 ppm to 500 ppm.
8 . The method of claim 1 comprising up to 0.1% by weight of peptide.
9 . The method of claim 1 wherein the carrier comprises lecithin.
10 . The method of claim 1 wherein said composition further comprises one or more additional ingredients selected from the group consisting of: ascorbic acid and ascorbic acid derivatives; lipoic acid; α-hydroxy acids; and tocotrienols and tocotrienol derivatives and vitamin E compositions enriched with tocotrienols or tocotrienol derivatives.
11 . The method of claim 1 wherein severe skin dryness, dullness, or lack of radiance are improved.
12 . A method of preventing or retarding exaggerated lines and wrinkles of peri-menopausal, menopausal, or post-menopausal skin comprising: applying to the skin tissue of a mammal in need of such regulation, a safe and effective amount of a composition comprising at least one Szeto-Schiller peptide and a dermatologically acceptable carrier.
13 . The method of claim 12 wherein the peptide is Tyr-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 1).
14 . The method of claim 12 wherein the peptide is Dmt-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 2).
15 . The method of claim 12 wherein the peptide is Phe-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO. 3).
16 . The method of claim 12 wherein the peptide is D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4).
17 . The method of claim 12 wherein the peptide is in the range from 10 ppm to 1000 ppm.
18 . The method of claim 17 wherein the peptide is in the range from 50 ppm to 500 ppm.
19 . The method of claim 12 comprising up to 0.1% by weight of peptide.
20 . The method of claim 12 wherein the carrier comprises lecithin.
21 . The method of claim 12 wherein said composition further comprises one or more additional ingredients selected from the group consisting of: ascorbic acid and ascorbic acid derivatives; lipoic acid; α-hydroxy acids; and tocotrienols and tocotrienol derivatives and vitamin E compositions enriched with tocotrienols or tocotrienol derivatives.
22 . A method of preventing or retarding the appearance of spider vessels or red blotchiness in peri-menopausal, menopausal, or post-menopausal skin comprising: applying to the skin tissue of a mammal in need of such regulation, a safe and effective amount of a composition comprising at least one Szeto-Schiller peptide and a dermatologically acceptable carrier.
23 . The method of claim 22 wherein the peptide is Tyr-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 1).
24 . The method of claim 22 wherein the peptide is Dmt-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 2).
25 . The method of claim 22 wherein the peptide is Phe-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO. 3).
26 . The method of claim 22 wherein the peptide is D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4).
27 . The method of claim 22 wherein the peptide is in the range from 10 ppm to 1000 ppm.
28 . The method of claim 27 wherein the peptide is the range from 50 ppm to 500 ppm.
29 . The method of claim 22 comprising up to 0.1% by weight of peptide.
30 . The method of claim 22 wherein the carrier comprises lecithin.
31 . The method of claim 22 wherein said composition further comprises one or more additional ingredients selected from the group consisting of: ascorbic acid and ascorbic acid derivatives; lipoic acid; α-hydroxy acids; and tocotrienols and tocotrienol derivatives and vitamin E compositions enriched with tocotrienols or tocotrienol derivatives.
32 . A method of improving the appearance aging skin comprising: applying to the skin tissue of a mammal in need of such regulation, a safe and effective amount of a composition containing D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4) in a dermatologically acceptable carrier.
33 . The method of claim 32 wherein the amount of D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4) is in the range from 10 ppm to 1000 ppm.
34 . The method of claim 33 wherein the amount of D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4) is in the range from 50 ppm to 500 ppm.
35 . The method of claim 32 comprising no more than 0.1% by weight of D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4).
36 . The method of claim 35 wherein said composition further comprises one or more additional ingredients selected from the group consisting of: ascorbic acid and ascorbic acid derivatives; lipoic acid; α-hydroxy acids; and tocotrienols and tocotrienol derivatives and vitamin E compositions enriched with tocotrienols or tocotrienol derivatives.
37 . The method of claim 35 wherein skin dryness, dullness, or lack of radiance are improved.
38 . The method of claim 35 wherein exaggerated lines and wrinkles are prevented or retarded.
39 . The method of claim 35 wherein the appearance of spider vessels or red blotchiness is prevented or retarded.
40 . A topical composition to prevent and repair skin aging, comprising: an effective amount of at least one Szeto-Schiller peptide and a dermatologically acceptable carrier.
41 . The topical composition of claim 40 further comprising one or more additional ingredients selected from the group consisting of: ascorbic acid and ascorbic acid derivatives; lipoic acid; α-hydroxy acids; and tocotrienols and tocotrienol derivatives and vitamin E compositions enriched with tocotrienols or tocotrienol derivatives.
42 . The topical composition of claim 40 wherein the peptide is in the range from 10 ppm to 1000 ppm.
43 . The topical composition of claim 42 wherein the peptide is in the range from 50 to 500 ppm.
44 . The topical composition of claim 40 comprising up to 0.1% by weight of peptide.
45 . The topical composition of claim 40 wherein the carrier comprises lecithin.
46 . A method for the prevention and treatment of skin aging comprising: applying a composition containing Szeto-Schiller peptide and a dermatologically acceptable carrier to skin tissue.
47 . The method of claim 46 wherein the peptide is Tyr-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 1).
48 . The method of claim 46 wherein the peptide is Dmt-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO: 2).
49 . The method of claim 46 wherein the peptide is Phe-D-Arg-Phe-Lys-NH 2 (SEQ. ID. NO. 3).
50 . The method of claim 46 wherein the peptide is D-Arg-Dmt-Lys-Phe-NH 2 (SEQ ID. NO: 4).
51 . The method of claim 46 wherein the peptide is in the range from 10 ppm to 1000 ppm.
52 . The method of claim 46 wherein the peptide is in the range from 50 to 500 ppm.
53 . The method of claim 46 comprising up to 0.1% by weight peptide.
54 . The method of claim 46 wherein the carrier comprises lecithin.
55 . The method of claim 46 wherein said composition further comprises one or more additional ingredients selected from the group consisting of: ascorbic acid and ascorbic acid derivatives; lipoic acid; α-hydroxy acids; and tocotrienols and tocotrienol derivatives and vitamin E compositions enriched with tocotrienols or tocotrienol derivatives.